Stockwinners Market Radar for March 04, 2018 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:08 EDT On The Fly: Top five weekend stock stories - Catch up on the weekend's top five stories with this list compiled by The Fly: 1. President Donald Trump has threatened European automakers with a tax on imports if the EU retaliates against his announced tariffs on aluminum and steel, according to Reuters. German carmakers Volkswagen (VLKAY), Daimler (DDAIF) and BMW (BMWYY) build vehicles in the U.S., the report noted. 2. Qualcomm (QCOM) shareholders on Tuesday are expected to decide on directors nominated by Broadcom (AVGO), which has pursued the former with a hostile $117B bid, according to The Wall Street Journal. Securing all six seats would give the Broadcom nominees a majority on Qualcomm's, making a takeover much more likely, the report added. 3. Department store stocks have rebounded in recent months, but they are not all likely to emerge as winners, Avi Salzman wrote in this week's edition of Barron's. Nordstrom (JWN) and TJX (TJX) appear to have the most staying power, with the former the more attractive choice in terms of valuation, he noted. Kohl's (KSS) and Macy's (M) are showing new life but need to prove they can repeat their fourth quarter performances, Salzman said, adding that JCPenney (JCP) and Dillard's (DDS) remain "tricky." 4. Disney (DIS) and Marvel Studios' "Black Panther" won the weekend box office, grossing $65.7M in its third outing and leaping past the $500M mark in North America and earning nearly $900M worldwide. The superhero film, which is now the tenth biggest pic of all time domestically not adjusted for inflation, scored 97% from Rotten Tomatoes and got an A+ CinemaScore from movie audiences. 5. Invesco (IVZ), saw a positive mention in Barron's, while L Brands (LB) and Fitbit (FIT) were mentioned cautiously.

18:13 EDT Box Office Battle: 'Black Panther' stays at number 1 with $65.7M in third outing - Disney (DIS) and Marvel Studios' "Black Panther" won the weekend box office, grossing $65.7M in its third outing and leaping past the $500M mark in North America and earning nearly $900M worldwide. The superhero film, which is now the tenth biggest pic of all time domestically not adjusted for inflation, scored 97% from Rotten Tomatoes and got an A+ CinemaScore from movie audiences. BOX OFFICE RUNNERS-UP: 21st Century Fox (FOXA) "Red Sparrow" debuted in second, earning an estimated $17M from 3,056 theaters. Behind it was another newcomer, the remake "Death Wish," which ended the weekend with $13M from 2,847 locations. Warner Bros.' (TWX) "Game Night" placed number four, grossing $10.7M for a domestic cume of $33.5M. Rounding out the top five, Sony's (SNE) "Peter Rabbit" ended the weekend with an estimated $10M for a domestic total of $84.1M. Other publicly traded companies in filmmaking include Viacom (VIAB), Comcast (CMCSA; CMCSK) and Lionsgate (LGF.A).

17:31 EDT Aimmune presents results from pivotal Phase 3 PALISADE Trial of AR101 - Aimmune Therapeutics announced that the results of its pivotal Phase 3 PALISADE trial of AR101 for the treatment of peanut allergy were presented at the 2018 American Academy of Allergy, Asthma & Immunology-World Allergy Organization Joint Congress in Orlando. Aimmune previously announced positive topline results of the PALISADE trial in February. PALISADE studied the efficacy and safety of AR101 in peanut-allergic patients by assessing reductions in clinical reactivity to peanut. In the primary analysis of patients ages 4-17, the trial met its primary and secondary endpoints, and AR101 demonstrated an encouraging tolerability and safety profile over the course of approximately one year of treatment. AR101 has U.S. Food and Drug Administration Breakthrough Therapy Designation for peanut-allergic patients ages 4-17, and Aimmune plans to submit a Biologics License Application for AR101 by the end of 2018. PALISADE enrolled a total of 554 patients ages 4-49. After approximately one year of treatment, patients completed an exit DBPCFC. In the trial's primary analysis of ages 4-17, patients were highly atopic and highly sensitive to peanut. The median tolerated dose of peanut protein in the entry DBPCFC was 10 mg, the equivalent of approximately 1/30 of a peanut, and, at baseline, 43% of patients had a peanut-specific IgE level greater than100 kU/L. Furthermore, more than half of the study participants had been diagnosed with asthma, nearly two thirds had multiple food allergies, and almost three quarters reported a history of anaphylaxis. In the primary analysis of ages 4-17, 296 patients from the AR101 arm completed the trial, compared to 116 patients from the placebo arm. At an Aimmune-sponsored event the same day as the late-breaking oral presentation, an exploratory analysis showed that patients with baseline psIgE less than or equal to 100 kU/L tended to have more favorable outcomes than those with baseline psIgE above 100 kU/L. The lower peanut-specific IgE group had a higher overall completer rate, a higher response rate at the 1000-mg endpoint, fewer GI-related withdrawals, and no severe treatment-related adverse events. There were no deaths or suspected, unexpected serious adverse reactions in the trial, and the incidence of serious adverse events was low, as 1.1% of AR101 patients experienced SAEs that were possibly related to treatment. One AR101 patient experienced a severe SAE of anaphylaxis and withdrew from the trial; this patient had high peanut-specific IgE at the start of the trial. There were no cases of anaphylactic shock observed in the trial.

17:12 EDT Frontier Communications activates strike contingency plan in West Virginia - Frontier Communications announced that it has activated its strike contingency plan in West Virginia. Members of the management team, outside contractors and representatives from other Frontier organizations will continue to provide West Virginia customers with quality customer service. The company is working to minimize disruptions to customer service.